🇺🇸 FDA
Pipeline program

KVD900 600 mg

KVD900-302a

Phase 3 small_molecule active

Quick answer

KVD900 600 mg for Hereditary Angioedema is a Phase 3 program (small_molecule) at KalVista Pharmaceuticals with 2 ClinicalTrials.gov record(s).

Program details

Company
KalVista Pharmaceuticals
Indication
Hereditary Angioedema
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials